Dr Bradley McGregor speaks to ecancer about the key studies regarding renal cancer at ASCO 2021.
He initially discusses the KEYNOTE-564 study regarding pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma. Dr McGregor then mentions the KEYNOTE-426 study saying that with a median follow-up of 42.8 months, this is the longest follow-up of an anti-PD–1/L1 immunotherapy combined with a VEGF/VEGFR inhibitor for first-line RCC. These results show that pembro + axitinib continues to demonstrate superior efficacy over sunitinib concerning OS, PFS, and ORR, with no new safety signals.
Dr McGregor also discusses the CANTATA trial and studies regarding non-clear cell renal carcinoma. To conclude, he discusses the trials in progress and what we can look forward to in the future.